## Supplemental Digital Content

**Supplementary Table 1.** (a) SF improvement logistic regression analysis: patients with UC from VISIBLE 1

| Dependent variable | Probability modelled: event = yes | | *n* |
|---|---|---|---|
| SF improvement at week 3 | | No | 339 |
| | | Yes | 42 |
| Predictors[a] | | OR (95% CI) | *P* value |
| Age | By 10 years | 0.84 (0.65–1.08) | 0.173 |
| BMI | By 1 point | 1.04 (0.97–1.11) | 0.234 |
| CS use at baseline | Yes vs. no | 0.56 (0.28–1.13) | 0.107 |
| Prior anti-TNFα treatment failure at baseline | Yes vs. no | 0.56 (0.27–1.14) | 0.109 |

SF improvement in patients with UC defined as a SF subscore of 0 on the Mayo score.
[a]Backward selection, *P* value threshold set to 0.25.
Anti-TNFα, antitumour necrosis factor alpha; BMI, body mass index; CI, confidence interval; CS, corticosteroid; OR, odds ratio; SF, stool frequency; UC, ulcerative colitis.

**Supplementary Table 1.** (b) SF improvement logistic regression analysis: patients with CD from VISIBLE 2

| Dependent variable | Probability modelled: event = yes | | *n* |
|---|---|---|---|
| SF improvement at week 3 | | No | 464 |
| | | Yes | 144 |
| Predictors[a] | | OR (95% CI) | *P* value |
| Sex | Female vs. male | 1.26 (0.86–1.83) | 0.232 |
| Geographic region | Others vs. Asia | 1.91 (0.72–5.02) | 0.191 |
| Prior anti-TNFα treatment failure at baseline | Yes vs. no | 0.79 (0.54–1.15) | 0.216 |

SF improvement in patients with CD was defined as a reduction of at least three stools for the mean of 7 days.
[a]Backward selection, *P* value threshold set to 0.25.
Anti-TNFα, antitumour necrosis factor; CD, Crohn's disease; CI, confidence interval; OR, odds ratio; SF, stool frequency.

**Supplementary Fig. 1.** Patient-reported CD symptoms during vedolizumab intravenous induction: weekly mean changes from baseline in PRO2 (endpoint comprised of the sum abdominal pain and stool frequency; error bars indicate negative SDs of the mean values) in (a) overall population, anti-TNFα-naive patients and anti-TNFα-experienced patients; and (b) overall population and patients with moderate or severe CD at baseline. Anti-TNFα, antitumour necrosis factor alpha; CD, Crohn's disease; CDAI, Crohn's disease activity index; PRO2, patient-reported outcome 2 composite score.




| Week | 0 | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|---|
| Overall, *n* | 609 | 605 | 607 | 607 | 606 | 607 | 606 |
| Anti-TNFα naive, *n* | 259 | 261 | 259 | 260 | 259 | 259 | 257 |
| Anti-TNFα experienced, *n* | 350 | 344 | 348 | 347 | 347 | 348 | 349 |

| Week | 0 | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|---|
| Overall, *n* | 609 | 605 | 607 | 607 | 606 | 607 | 606 |
| Moderate CD (CDAI ≥220–330), *n* | 381 | 379 | 380 | 379 | 379 | 379 | 379 |
| Severe CD (CDAI >330–450), *n* | 228 | 226 | 227 | 228 | 227 | 228 | 227 |